Moreover, FGFR2 mutations have been reported in a diverse range of cancer types including BC, and FGFR inhibitors reported to have a direct anti-tumor effect on cancer cells (Jang et al., 2000; Helsten et al., 2016). Here, FGFR2 is linked to breast cancer.